Document Detail


Increased expression of osteopontin in patients with triple-negative breast cancer.
MedLine Citation:
PMID:  18452545     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Patients with triple-negative [oestrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor 2 (HER-2/neu) negative] breast cancer, accounting for about 15% of breast cancer cases, are associated with aggressive histology, poor prognosis and shorter survival. Osteopontin is a chemokine-like phosphorylated glycoprotein that plays important role in cancer progression and is found to be a metastasis-associated protein in breast cancer. The goal of the study was to evaluate osteopontin protein expression levels in triple-negative breast carcinomas to determine if they correlated with clinicopathological parameters, thus providing additional support for osteopontin functioning and better understanding of triple-negative breast cancer. MATERIALS AND METHODS: A database of 239 patients, in whom all three markers (ER, PR, and HER-2/neu) were available, was reviewed. We performed osteopontin protein expression analyses by means of immunohistochemistry on 117 breast carcinoma tissue samples, and then assessed the mean value of osteopontin expression against triple-negative status and clinicopathological parameters. RESULTS: Of the 239 patients in the study, 47 were classified as triple negative. Of the 117 osteopontin-test patients in this cohort, mean osteopontin levels were significantly higher in the triple-negative breast cancers than in non-triple-negative subtype (P = 0.035). TNM (tumours, nodes, metastases) stage were significantly associated with osteopontin levels (P = 0.038). Univariate analysis showed tumour cell osteopontin positivity above an optimized cut-point to be significantly associated with decreased disease-free survival, but not overall survival. In the multivariate model, osteopontin was an independent prognostic factor for disease-free survival. CONCLUSIONS: Patients with osteopontin overexpression develop predominantly triple-negative tumours. Osteopontin overexpression is associated with tumour aggressiveness and poor prognosis.
Authors:
X Wang; L Chao; G Ma; L Chen; B Tian; Y Zang; J Sun
Related Documents :
8758245 - Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in si...
1949915 - Expression of prognostic factors (egfr, er) by immunohistochemical staining method in m...
20842115 - Risk of breast cancer according to clinicopathologic features among long-term survivors...
3285555 - Radioligand-labeled binding assay and immunochemical assay for estrogen receptor in 115...
17137045 - Inflammatory breast cancer.
25237365 - The effects of tamoxifen in combination with tranilast on cxcl12-cxcr4 axis and invasio...
Publication Detail:
Type:  Journal Article     Date:  2008-04-30
Journal Detail:
Title:  European journal of clinical investigation     Volume:  38     ISSN:  1365-2362     ISO Abbreviation:  Eur. J. Clin. Invest.     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-05-20     Completed Date:  2008-08-01     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0245331     Medline TA:  Eur J Clin Invest     Country:  England    
Other Details:
Languages:  eng     Pagination:  438-46     Citation Subset:  IM    
Affiliation:
Department of Breast Cancer, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Breast Neoplasms / chemistry*,  mortality,  pathology
Databases, Factual
Disease-Free Survival
Female
Follow-Up Studies
Gene Expression
Humans
Immunohistochemistry
Lymphatic Metastasis
Middle Aged
Osteopontin / analysis*
Phenotype
Proportional Hazards Models
Receptor, erbB-2*
Receptors, Estrogen*
Receptors, Progesterone*
Survival Rate
Tumor Markers, Biological / analysis*
Up-Regulation
Chemical
Reg. No./Substance:
0/Receptors, Estrogen; 0/Receptors, Progesterone; 0/Tumor Markers, Biological; 106441-73-0/Osteopontin; EC 2.7.10.1/Receptor, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Monocyte count is an underlying marker of lacunar subtype of hypertensive small vessel disease.
Next Document:  Active bacterial community structure along vertical redox gradients in Baltic Sea sediment.